Acute Lymphoblastic Leukemia Treatment Market: By Disease Type (Acute B-lymphoblastic Leukemia, Acute T-lymphoblastic Leukemia),By Treatment Type ( Chemotherapy ( Corticosteroids, Colony-stimulating Factors, Tyrosine Kinase Inhibitors, Others), Immunotherapy, Others)),By Route of Administration ( Oral, Parenteral),By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography.  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Acute lymphoblastic leukemia Treatment Market size was valued at USD 2,334.5 million in 2022 and is poised to grow at a significant CAGR of 5.3% from 2023-2029.Types of leukemia occurs due to the accumulation and overproduction of cancerous white blood cells known as lymphoblasts in the bone marrow. It may spread to other body organs such as liver, spleen, lymph nodes, and central nervous system among others. It mostly occurs in children and sometimes in children with 2-5 years of age and rarely occurs in old age population. Common signs and symptoms associated with acute lymphoblastic leukemia include fatigue, fever, frequent infections, bruising, weight loss, joint pains, and swollen lymph glands among others. It can be diagnosed by bone marrow test, blood test, ultrasound, MRI, and CT scans among others. Acute lymphoblastic leukemia treatment market is growing at lucrative rate owing to increase in the prevalence of acute lymphoblastic leukemia prevalence in developing countries due to genetic factors. The rise in R&D activities for the innovation of newer chemotherapy and immunotherapy molecules is anticipated to fuel the market. Moreover, acquisitions and mergers, collaborations, and product launchings are the key strategies followed by the companies for dominating the acute lymphoblastic leukemia treatment industry. 

Global Acute Lymphoblastic Leukemia Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

0.053%

Largest Market

Europe

Fastest Growing Market

North-America
Acute Lymphoblastic Leukemia Treatment Market Dynamics

Increase in the incidence of acute lymphoblastic leukemia, rise in the R&D activities for the innovation of novel therapies, growing in healthcare expenditure, and advancement in molecular biology and pharmacology for development of novel drugs are anticipated to fuel the market. In addition, rise in awareness programs and increase in healthcare expenditure are expected propel the growth of the market over the forecast period. However, stringent regulatory policies, high cost of treatment, adverse effects associated with the treatment, and complications with chemotherapy are expected to hinder the growth of the market over the forecast period.

Key Features of the Reports

  • The acute lymphoblastic leukemia treatment market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Acute Lymphoblastic Leukemia Treatment Market Segmentation

By Disease Type
  • Acute B-lymphoblastic Leukemia
  • Acute T-lymphoblastic Leukemia
  • Others
By Treatment Type
  • Chemotherapy
    • Corticosteroids
    • Colony-stimulating Factors
    • Tyrosine Kinase Inhibitors
    • Others
  • Immunotherapy
  • Others
By Route of Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Europe
  • Asia Pacifi
  • Latin America
  • Middle East Africa

Frequently Asked Questions

The key segments covered in the Acute Lymphoblastic Leukemia Treatment Market are technology, components, application, and end-users.

The Acute Lymphoblastic Leukemia Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The Acute Lymphoblastic Leukemia Treatment Market key players are Pfizer, Inc. (U.S.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Genzyme Corporation (U.S.), Talon Therapeutic, Inc. (U.S.), Erytech Pharma (France), Baxter International Inc. (U.S.), Novartis AG (Switzerland), Rare Disease Therapeutics, Inc. (U.S.)

1. Executive Summary

2. Global Acute Lymphoblastic Leukemia Treatment Market Introduction

  •   2.1. Global Acute Lymphoblastic Leukemia Treatment Market Taxonomy
  •   2.2. Global Acute Lymphoblastic Leukemia Treatment Market Definitions
    • 2.2.1. Disease Type      
    • 2.2.2. Treatment Type    
    • 2.2.3. Rout of Administration        
    • 2.2.4. Distribution Channel

3. Global Acute Lymphoblastic Leukemia Treatment Market Dynamics

  •  3.1. Drivers
  •  3.2. Restraints
  •  3.3. Opportunities/Unmet Needs of the Market
  •  3.4. Trends
  •  3.5. Global Acute Lymphoblastic Leukemia Treatment Market Dynamic Factors - Impact Analysis
  •  3.6. Global Acute Lymphoblastic Leukemia Treatment Market Competition Landscape
  •  3.7. Epidemiology

4. Global Acute Lymphoblastic Leukemia Treatment Market Analysis,2018-2022 and Forecast, 2023-2029 

  •  4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
  •  4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
  •  4.3. Market OpportunityAnalysis

5. Global Acute Lymphoblastic Leukemia Treatment Market, By Disease Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  5.1. Acute B-lymphoblastic Leukemia
    •   5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   5.1.3. Market Opportunity Analysis
  •  5.2. Acute T-lymphoblastic Leukemia
    •   5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   5.2.3. Market Opportunity Analysis
  •  5.3. Others
    •   5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   5.3.3. Market Opportunity Analysis

6. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Treatment Type,2018-2022 and Forecast, 2023-2029 

  •  6.1. Chemotherapy
    •   6.1.1. Corticosteroids
      •    6.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      •    6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      •    6.1.1.3. Market Opportunity Analysis
    •   6.1.2. Colony-stimulating Factors
      •    6.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      •    6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      •    6.1.2.3. Market Opportunity Analysis
    •   6.1.3. Tyrosine Kinase Inhibitors
      •    6.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      •    6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      •    6.1.3.3. Market Opportunity Analysis
    •  6.1.4. Others
      •    6.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
      •    6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      •    6.1.4.3. Market Opportunity Analysis
  •  6.2. Immunotherapy
    •    6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •    6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •    6.2.3. Market Opportunity Analysis
  •  6.3. Others
    •   6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   6.3.3. Market Opportunity Analysis

7. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Route of Administration, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  7.1. Oral
    •   7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   7.1.3. Market Opportunity Analysis
  •  7.2. Parenteral
    •   7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   7.2.3. Market Opportunity Analysis

8. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Distribution Channel, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  8.1. Hospital Pharmacies
    •   8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   8.1.3. Market Opportunity Analysis
  •  8.2. Retail Pharmacies
    •   8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   8.2.3. Market Opportunity Analysis
  •  8.3. Online Pharmacies Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   8.3.3. Market Opportunity Analysis

9. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  9.1. North America
    •   9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   9.1.3. Market Opportunity Analysis
  •  9.2. Europe
    •   9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   9.2.3. Market Opportunity Analysis
  •  9.3. Asia-Pacific
    •   9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   9.3.3. Market Opportunity Analysis
  •  9.4. Latin America
    •   9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   9.4.3. Market Opportunity Analysis
  •  9.5. Middle East and Africa
    •   9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)
    •   9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    •   9.5.3. Market Opportunity Analysis
  •  9.6. Global Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2023-2029

10. North America Acute Lymphoblastic Leukemia Treatment MarketAnalysis,2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  10.1. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
    •   10.1.1. Acute B-lymphoblastic Leukemia
    •   10.1.2. Acute T-lymphoblastic Leukemia
    •   10.1.3. Others
  •  10.2. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    •   10.2.1. Chemotherapy
      •     10.2.1.1. Corticosteroids
      •     10.2.1.2. Colony-stimulating Factors
      •     10.2.1.3. Tyrosine Kinase Inhibitors
      •     10.2.1.4. Others
    •   10.2.2. Immunotherapy
    •   10.2.3. Others
  •  10.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)       
    •    10.3.1. Oral
    •    10.3.2. Parenteral
  •  10.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)             
    •    10.4.1. Hospital Pharmacies
    •    10.4.2. Retail Pharmacies
    •    10.4.3. Online Pharmacies
  •  10.5. Country Analysis 2016 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    •   10.5.1. U.S.
    •   10.5.2. Canada
  •  10.6. North America Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2023-2029
  •  10.7. North America Acute Lymphoblastic Leukemia Treatment Market Dynamics Trends

11. Europe Acute Lymphoblastic Leukemia Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  11.1. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
    •   11.1.1. Acute B-lymphoblastic Leukemia
    •   11.1.2. Acute T-lymphoblastic Leukemia
    •   11.1.3. Others
  •  11.2. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    •   11.2.1. Chemotherapy
      •     11.2.1.1. Corticosteroids
      •     11.2.1.2. Colony-stimulating Factors
      •     11.2.1.3. Tyrosine Kinase Inhibitors
      •     11.2.1.4. Others
    •   11.2.2. Immunotherapy
    •   11.2.3. Others
  •  11.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    •   11.3.1. Oral
    •   11.3.2. Parenteral
  •  11.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)             
    • 11.4.1. Hospital Pharmacies
    •    11.4.2. Retail Pharmacies
    •    11.4.3. Online Pharmacies
  •  11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    •   11.5.1. Germany
    •   11.5.2. UK
    •   11.5.3. France
    •   11.5.4. Spain
    •   11.5.5. Italy
    •   11.5.6. Russia
    •   11.5.7. Poland
    •   11.5.8. Rest of Europe
  •  11.6. Europe Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2023-2029
  •  11.7. Europe Acute Lymphoblastic Leukemia Treatment Market Dynamics Trends

12. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  12.1. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
    •   12.1.1. Acute B-lymphoblastic Leukemia
    •   12.1.2. Acute T-lymphoblastic Leukemia
    •   12.1.3. Others
  •  12.2. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    •   12.2.1. Chemotherapy
      •    12.2.1.1. Corticosteroids
      •    12.2.1.2. Colony-stimulating Factors
      •    12.2.1.3. Tyrosine Kinase Inhibitors
      •    12.2.1.4. Others
    •   12.2.2. Immunotherapy
    •   12.2.3. Others
  •  12.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)       
    •    12.3.1. Oral
    •    12.3.2. Parenteral
  •  12.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)             
    •    12.4.1. Hospital Pharmacies
    •    12.4.2. Retail Pharmacies
    •    12.4.3. Online Pharmacies
  •  12.5. Country Analysis2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    •   12.5.1. Japan
    •   12.5.2. China
    •   12.5.3. India
    •   12.5.4. ASEAN
    •   12.5.5. Australia & New Zealand
    •   12.5.6. Rest of Asia-Pacific
  •  12.6. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2023-2029
  •  12.7. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market Dynamics Trends

13. Latin America Acute Lymphoblastic Leukemia Treatment Market Analysis, 2012 - 2012 - 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  13.1. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
    •    13.1.1. Acute B-lymphoblastic Leukemia
    •    13.1.2. Acute T-lymphoblastic Leukemia
    •    13.1.3. Others
  •  13.2. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  •    13.2.1. Chemotherapy
      •     13.2.1.1. Corticosteroids
      •     13.2.1.2. Colony-stimulating Factors
      •     13.2.1.3. Tyrosine Kinase Inhibitors
      •     13.2.1.4. Others
    •    13.2.2. Immunotherapy
    •    13.2.3. Others
  •  13.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)       
    •     13.3.1. Oral
    •     13.3.2. Parenteral
  •  13.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)             
    • 13.4.1. Hospital Pharmacies
    •    13.4.2. Retail Pharmacies
    •    13.4.3. Online Pharmacies
  •  13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    •    13.5.1. Brazil
    •    13.5.2. Mexico
    •    13.5.3. Argentina
    •    13.5.4. Venezuela
    •    13.5.5. Rest of Latin America
  •  13.6. Latin America Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2023-2029
  •  13.7. Latin America Acute Lymphoblastic Leukemia Treatment Market Dynamics Trends

14. Middle East and Africa Acute Lymphoblastic Leukemia Treatment Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn)

  •  14.1. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
    •   14.1.1. Acute B-lymphoblastic Leukemia
    •   14.1.2. Acute T-lymphoblastic Leukemia
    •   14.1.3. Others
  •  14.2. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    •   14.2.1. Chemotherapy
      •     14.2.1.1. Corticosteroids
      •     14.2.1.2. Colony-stimulating Factors
      •     14.2.1.3. Tyrosine Kinase Inhibitors
      •     14.2.1.4. Others
    •   14.2.2. Immunotherapy
    •   14.2.3. Others
  •  14.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)       
    • 14.3.1. Oral
    •    14.3.2. Parenteral
  •  14.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)             
    • 14.4.1. Hospital Pharmacies
    •     14.4.2. Retail Pharmacies
    •     14.4.3. Online Pharmacies
  •  14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    •   14.5.1. Gulf Cooperation Council (GCC) Countries
    •   14.5.2. Israel
    •   14.5.3. South Africa
    •   14.5.4. Rest of MEA
  •  14.6. MEA Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2023-2029
  •  14.7. MEA Acute Lymphoblastic Leukemia Treatment Market Dynamics Trends

15. Competition Landscape

  •  15.1. Strategic Dashboard of Top Market Players
  •  15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)       
    •    15.2.1. Pfizer, Inc. (U.S.)
    •    15.2.2. Sigma-Tau Pharmaceuticals, Inc. (U.S.)
    •    15.2.3. GlaxoSmithKline plc (U.K.)
    •    15.2.4. Genzyme Corporation (U.S.)
    •    15.2.5. Talon Therapeutic, Inc. (U.S.)
    •    15.2.6. Erytech Pharma (France)
    •    15.2.7. Baxter International Inc. (U.S.)
    •    15.2.8. Novartis AG (Switzerland)
    •    15.2.9. Rare Disease Therapeutics, Inc. (U.S.)

16. Research Methodology

17. Key Assumptions and Acronyms

  • Pfizer, Inc. (U.S.)
  • Sigma-Tau Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Genzyme Corporation (U.S.)
  • Talon Therapeutic, Inc. (U.S.)
  • Erytech Pharma (France)
  • Baxter International Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Rare Disease Therapeutics, Inc. (U.S.)